Timber pharmaceuticals announces notification of nyse american continued listing deficiency

Basking ridge, nj, aug. 29, 2022 (globe newswire) -- via newmediawire -- timber pharmaceuticals, inc. ("timber" or the “company”) (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it had received a deficiency letter ("letter") from nyse american llc ("nyse american" or the "exchange") stating that the company is not in compliance with the continued listing standards as set forth in section 1003(f)(v) of the nyse american company guide ("company guide").
TMBR Ratings Summary
TMBR Quant Ranking